Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study
Authors' conclusion
Tirzepatide significantly reduced HbA1c and body weight in adults with T1D. A randomized controlled trial is needed to establish efficacy and safety of this drug in T1D.
Study context
- Population
- Adults with T1D; mean age 42 ± 8 years, 54% female, mean body mass index (BMI) 36.7 ± 5.3 kg/m²
- Participants
- 26 adults
- Outcome
- Reduction in HbA1c and percent change in body weight from baseline
- Follow-up
- Over 8 months
Methodological detailssingle-centre, proof of concept
- Single-centre
- Proof of concept
Main finding
As reported in the abstract
3, 6 and 8 months
- Hemoglobin A1c (HbA1c) reduction at 3 months (significant)
- 0.45%
- HbA1c reduction at 8 months (significant)
- 0.59%
- Body weight reduction at 3 months (significant)
- 3.4%
- Body weight reduction at 6 months (significant)
- 10.5%
- Body weight reduction at 8 months (significant)
- 10.1%
Observational data: associations, not effects.
Secondary outcomes
Continuous glucose monitoring (CGM) metrics: TIR (70-180 mg/dL), TITR (70-140 mg/dL), TAR (>180 mg/dL) · 3 months
- TIR increase
- +12.6%, P = .002
- TITR increase
- +10.7%, P = .0016
- TAR decrease
- −12.6%, P = .002
- Changes sustained over 8 months
Safety
Safety and tolerability
- Discontinued medication
- 2 patients
- Relatively safe and well tolerated
Original publication
Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study. J Diabetes Sci Technol. Published 5 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →